PT  - JOURNAL ARTICLE
AU  - Chen, Chaoran
AU  - Nadeau, Sarah
AU  - Topolsky, Ivan
AU  - Manceau, Marc
AU  - Huisman, Jana S.
AU  - Jablonski, Kim Philipp
AU  - Fuhrmann, Lara
AU  - Dreifuss, David
AU  - Jahn, Katharina
AU  - Beckmann, Christiane
AU  - Redondo, Maurice
AU  - Kobel, Olivier
AU  - Noppen, Christoph
AU  - Risch, Lorenz
AU  - Risch, Martin
AU  - Wohlwend, Nadia
AU  - Kas, Sinem
AU  - Bodmer, Thomas
AU  - Roloff, Tim
AU  - Stange, Madlen
AU  - Egli, Adrian
AU  - Eckerle, Isabella
AU  - Denes, Rebecca
AU  - Feldkamp, Mirjam
AU  - Nissen, Ina
AU  - Santacroce, Natascha
AU  - Burcklen, Elodie
AU  - Aquino, Catharine
AU  - de Gouvea, Andreia Cabral
AU  - Moccia, Maria Domenica
AU  - Grüter, Simon
AU  - Sykes, Timothy
AU  - Opitz, Lennart
AU  - White, Griffin
AU  - Neff, Laura
AU  - Popovic, Doris
AU  - Patrignani, Andrea
AU  - Tracy, Jay
AU  - Schlapbach, Ralph
AU  - Dermitzakis, Emmanouil T.
AU  - Harshman, Keith
AU  - Xenarios, Ioannis
AU  - Pegeot, Henri
AU  - Cerutti, Lorenzo
AU  - Penet, Deborah
AU  - Blin, Anthony
AU  - Elies, Melyssa
AU  - Althaus, Christian
AU  - Beisel, Christian
AU  - Beerenwinkel, Niko
AU  - Ackermann, Martin
AU  - Stadler, Tanja
TI  - Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
AID  - 10.1101/2021.03.05.21252520
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.05.21252520
4099  - http://medrxiv.org/content/early/2021/03/09/2021.03.05.21252520.short
4100  - http://medrxiv.org/content/early/2021/03/09/2021.03.05.21252520.full
AB  - In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now coined B.1.1.7. Based on the UK data and later additional data from other countries, a transmission advantage of around 40-80% was estimated for this variant [1, 2, 3].In Switzerland, since spring 2020, we perform whole genome sequencing of SARS-CoV-2 samples obtained from a large diagnostic lab (Viollier AG) on a weekly basis for genomic surveillance. The lab processes SARS-CoV-2 samples from across Switzerland. Based on a total of 7631 sequences obtained from samples collected between 14.12.2020 and 11.02.2021 at Viollier AG, we determine the relative proportion of the B.1.1.7 variant on a daily basis. In addition, we use data from a second lab (Dr Risch) screening all their samples for the B.1.1.7 variant. These two datasets represent 11.5 % of all SARS-CoV-2 confirmed cases across Switzerland during the considered time period. They allow us to quantify the transmission advantage of the B.1.1.7 variant on a national and a regional scale.Taking all our data and estimates together, we propose a transmission advantage of 49-65% of B.1.1.7 compared to the other circulating variants. Further, we estimate the effective reproductive number through time for B.1.1.7 and the other variants, again pointing to a higher transmission rate of B.1.1.7. In particular, for the time period 01.01.2021-17.01.2021, we estimate an average reproductive number for B.1.1.7 of 1.28 [1.07-1.49] while the estimate for the other variants is 0.83 [0.63-1.03], based on the total number of confirmed cases and our Viollier sequencing data. Switzerland tightened measures on 18.01.2021. A comparison of the empirical confirmed case numbers up to 20.02.2021 to a very simple model using the estimates of the reproductive number from the first half of January provides indication that the rate of spread of all variants slowed down recently.In summary, the dynamics of increase in frequency of B.1.1.7 is as expected based on the observations in the UK. Our plots are available online and constantly updated with new data to closely monitor the changes in absolute numbers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTS acknowledges funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30_196267 and 31CA30_196348). CA received funding from the European Union Horizon 2020 research and innovation programme - project EpiPose (No 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics commission (Ethikkommission Nordwest- und Zentralschweiz) confirmed that our study is exempt from ethical oversight as it only considers viral RNA but no human data. The final letter is attached.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll used data and code are publicly available. https://github.com/cevo-public/Quantification-of-the-spread-of-a-SARS-CoV-2-variant